375 related articles for article (PubMed ID: 17525627)
1. The significance of Ki-67 proliferative index and cyclin D1 expression of dysplastic nevi in the biologic spectrum of melanocytic lesions.
Lebe B; Pabuççuoğlu U; Ozer E
Appl Immunohistochem Mol Morphol; 2007 Jun; 15(2):160-4. PubMed ID: 17525627
[TBL] [Abstract][Full Text] [Related]
2. Cyclin D1 and D3 expression in melanocytic skin lesions.
Alekseenko A; Wojas-Pelc A; Lis GJ; Furgał-Borzych A; Surówka G; Litwin JA
Arch Dermatol Res; 2010 Sep; 302(7):545-50. PubMed ID: 20496072
[TBL] [Abstract][Full Text] [Related]
3. IMP-3 EXPRESSION IN BENIGN MELANOCYTIC NEVI, DYSPLASTIC NEVI AND MALIGNANT MELANOMA: PRELIMINARY FINDINGS IN BULGARIAN PATIENTS.
Chokoeva AA; Ananiev J; Wollina U; Tana C; Lotti T; Cardoso JC; Tchernev G
J Biol Regul Homeost Agents; 2015; 29(3):695-9. PubMed ID: 26403409
[TBL] [Abstract][Full Text] [Related]
4. Cyclin D1 expression in melanocytic lesions of the skin.
Ramirez JA; Guitart J; Rao MS; Diaz LK
Ann Diagn Pathol; 2005 Aug; 9(4):185-8. PubMed ID: 16084449
[TBL] [Abstract][Full Text] [Related]
5. Comparison of pHH3, Ki-67, and survivin immunoreactivity in benign and malignant melanocytic lesions.
Nasr MR; El-Zammar O
Am J Dermatopathol; 2008 Apr; 30(2):117-22. PubMed ID: 18360113
[TBL] [Abstract][Full Text] [Related]
6. Minichromosome maintenance protein expression in benign nevi, dysplastic nevi, melanoma, and cutaneous melanoma metastases.
Boyd AS; Shakhtour B; Shyr Y
J Am Acad Dermatol; 2008 May; 58(5):750-4. PubMed ID: 18249467
[TBL] [Abstract][Full Text] [Related]
7. Alterations of mismatch repair protein expression in benign melanocytic nevi, melanocytic dysplastic nevi, and cutaneous malignant melanomas.
Hussein MR; Roggero E; Sudilovsky EC; Tuthill RJ; Wood GS; Sudilovsky O
Am J Dermatopathol; 2001 Aug; 23(4):308-14. PubMed ID: 11481522
[TBL] [Abstract][Full Text] [Related]
8. Atypical melanocytic nevi of the genital type with a discussion of reciprocal parenchymal-stromal interactions in the biology of neoplasia.
Clark WH; Hood AF; Tucker MA; Jampel RM
Hum Pathol; 1998 Jan; 29(1 Suppl 1):S1-24. PubMed ID: 9445124
[TBL] [Abstract][Full Text] [Related]
9. Expression of the embryonic morphogen Nodal in cutaneous melanocytic lesions.
Yu L; Harms PW; Pouryazdanparast P; Kim DS; Ma L; Fullen DR
Mod Pathol; 2010 Sep; 23(9):1209-14. PubMed ID: 20495543
[TBL] [Abstract][Full Text] [Related]
10. Expression pattern of type IV collagen in sporadic dysplastic melanocytic nevi.
Lebe B; Pabuççuoglu U; Ozer E
Anal Quant Cytol Histol; 2008 Oct; 30(5):291-6. PubMed ID: 18980161
[TBL] [Abstract][Full Text] [Related]
11. α-Methylacyl-coenzyme A racemase (AMACR, p504s) is a marker to distinguish malignant melanomas from dysplastic nevi and melanocytic nevi.
Abbas M; Ploch EM; Wehling J; Schipper E; Janciauskiene S; Kreipe HH; Jonigk D
Tumour Biol; 2014 Dec; 35(12):12015-20. PubMed ID: 25149154
[TBL] [Abstract][Full Text] [Related]
12. Benign melanocytic lesions: risk markers or precursors of cutaneous melanoma?
Skender-Kalnenas TM; English DR; Heenan PJ
J Am Acad Dermatol; 1995 Dec; 33(6):1000-7. PubMed ID: 7490345
[TBL] [Abstract][Full Text] [Related]
13. G1 cell cycle regulators in congenital melanocytic nevi. Comparison with acquired nevi and melanomas.
Stefanaki C; Stefanaki K; Antoniou C; Argyrakos T; Stratigos A; Patereli A; Katsambas A
J Cutan Pathol; 2008 Sep; 35(9):799-808. PubMed ID: 18494826
[TBL] [Abstract][Full Text] [Related]
14. Expression of insulin-like growth factor-binding protein 2 in melanocytic lesions.
Wang H; Shen SS; Wang H; Diwan AH; Zhang W; Fuller GN; Prieto VG
J Cutan Pathol; 2003 Nov; 30(10):599-605. PubMed ID: 14744083
[TBL] [Abstract][Full Text] [Related]
15. Proliferative activity of primary cutaneous melanocytic tumours.
Kuwata T; Kitagawa M; Kasuga T
Virchows Arch A Pathol Anat Histopathol; 1993; 423(5):359-64. PubMed ID: 7906909
[TBL] [Abstract][Full Text] [Related]
16. Proliferation, apoptosis, and survivin expression in a spectrum of melanocytic nevi.
Florell SR; Bowen AR; Hanks AN; Murphy KJ; Grossman D
J Cutan Pathol; 2005 Jan; 32(1):45-9. PubMed ID: 15660660
[TBL] [Abstract][Full Text] [Related]
17. Beclin 1 and LC3 autophagic gene expression in cutaneous melanocytic lesions.
Miracco C; Cevenini G; Franchi A; Luzi P; Cosci E; Mourmouras V; Monciatti I; Mannucci S; Biagioli M; Toscano M; Moretti D; Lio R; Massi D
Hum Pathol; 2010 Apr; 41(4):503-12. PubMed ID: 20004946
[TBL] [Abstract][Full Text] [Related]
18. A subgroup of melanocytic nevi on the distal lower extremity (ankle) shares features of acral nevi, dysplastic nevi, and melanoma in situ: a potential misdiagnosis of melanoma in situ.
Khalifeh I; Taraif S; Reed JA; Lazar AF; Diwan AH; Prieto VG
Am J Surg Pathol; 2007 Jul; 31(7):1130-6. PubMed ID: 17592281
[TBL] [Abstract][Full Text] [Related]
19. A distinctive melanocytic lesion associated with melanoma-prone dysplastic naevus syndrome: the hybrid naevus.
Schubert C; Parwaresch R; Rudolph P
Virchows Arch; 2001 Feb; 438(2):166-72. PubMed ID: 11253119
[TBL] [Abstract][Full Text] [Related]
20. Expression of protease-activated receptors 1 and 2 in melanocytic nevi and malignant melanoma.
Massi D; Naldini A; Ardinghi C; Carraro F; Franchi A; Paglierani M; Tarantini F; Ketabchi S; Cirino G; Hollenberg MD; Geppetti P; Santucci M
Hum Pathol; 2005 Jun; 36(6):676-85. PubMed ID: 16021575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
